Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Gain of glycosylation in integrin α3 causes lung disease and nephrotic syndrome
Nayia Nicolaou, … , Kirsten Y. Renkema, Arnoud Sonnenberg
Nayia Nicolaou, … , Kirsten Y. Renkema, Arnoud Sonnenberg
Published November 1, 2012
Citation Information: J Clin Invest. 2012;122(12):4375-4387. https://doi.org/10.1172/JCI64100.
View: Text | PDF
Research Article Nephrology

Gain of glycosylation in integrin α3 causes lung disease and nephrotic syndrome

  • Text
  • PDF
Abstract

Integrins are transmembrane αβ glycoproteins that connect the extracellular matrix to the cytoskeleton. The laminin-binding integrin α3β1 is expressed at high levels in lung epithelium and in kidney podocytes. In podocytes, α3β1 associates with the tetraspanin CD151 to maintain a functional filtration barrier. Here, we report on a patient homozygous for a novel missense mutation in the human ITGA3 gene, causing fatal interstitial lung disease and congenital nephrotic syndrome. The mutation caused an alanine-to-serine substitution in the integrin α3 subunit, thereby introducing an N-glycosylation motif at amino acid position 349. We expressed this mutant form of ITGA3 in murine podocytes and found that hyperglycosylation of the α3 precursor prevented its heterodimerization with β1, whereas CD151 association with the α3 subunit occurred normally. Consequently, the β1 precursor accumulated in the ER, and the mutant α3 precursor was degraded by the ubiquitin-proteasome system. Thus, these findings uncover a gain-of-glycosylation mutation in ITGA3 that prevents the biosynthesis of functional α3β1, causing a fatal multiorgan disorder.

Authors

Nayia Nicolaou, Coert Margadant, Sietske H. Kevelam, Marc R. Lilien, Michiel J.S. Oosterveld, Maaike Kreft, Albertien M. van Eerde, Rolph Pfundt, Paulien A. Terhal, Bert van der Zwaag, Peter G.J. Nikkels, Norman Sachs, Roel Goldschmeding, Nine V.A.M. Knoers, Kirsten Y. Renkema, Arnoud Sonnenberg

×

Figure 5

The α3A349S mutation disrupts α3 heterodimerization with β1 but not CD151 binding.

Options: View larger image (or click on image) Download as PowerPoint
The α3A349S mutation disrupts α3 heterodimerization with β1 but not CD15...
(A) Podocytes expressing α3WT or α3A349S were lysed, and the α3 subunit was precipitated using antibodies against the cytoplasmic tail (29A3) or the extracellular domain (J143 and P1B5). Precipitated α3 and β1 were detected by Western blotting. (B) β1 was precipitated from podocyte lysates using 9EG7 or MB1.2, and α3 and β1 were detected by Western blotting. (C) The α3 subunit was precipitated using 29A3 from tissue lysates of the patient and a healthy individual, and α3 and β1 were detected by Western blotting. (D) FLAG-tagged CD151 was precipitated from podocyte lysates using M2 against the FLAG-tag, 11G5 against CD151, or TS151R that recognizes the QRD sequence in CD151 when not in complex with α3. J143 was included as a control. CD151, α3, and β1 were subsequently detected by Western blotting.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts